Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Cancer often returns after successful therapy, but why?
OMRF researchers found mutations in PDGF receptor beta can trigger two rare diseases.
OMRF has received a five-year, $1.7 million grant to look at how DNA replicates itself.
Fish, frogs and worms have become key players in the fight against disease.
OMRF received a grant for breakthrough research studying fruit fly hearts.